Aug 15
Opportunity
Participants expect a simple and convenient experience participating on clinical trials. To accomplish this goal, sponsors should consider the type, design and delivery of device (e.g., personal device, provided by study, etc.) for participants to achieve accessibility, flexibility, convenience and maintain privacy.
Considerations to Help Action the Opportunity
- Understand if the clinical trial design supports the applications of digital patient solutions
- Understand the needs and preferences of the participants taking part in the trial
- Does the population have access to devices and data plans, or would they need these to be provisioned?
- What devices would participants already have that could be used for clinical trials (e.g., wearables / sensors, glucometers, weighing scales, phones / tablets, etc.)?
- Understand impact on health equity (i.e., geographic, socioeconomic barriers) when implementing digital solutions
- Partner with sites to gain their input on the impact of multiple services, training, and technology implementation
- Understand how the device may impact data integrity, regulatory landscape, site implementation and overall costs
- Define how technology is designed, communicated and delivered for / to participants
- Define backup options (e.g., when a participant is unable to connect to device)
Value and Potential Benefits
- Increases access and ease of participation for participants on clinical trials by potentially reducing the number of site visits
- Allows for more robust datasets with improved data compliance and quality by enabling direct entry and near real-time review of data
Related Blog Posts
Digital Protocols Are At An Inflection Point: A Conversation With Novartis And TransCelerate Leaders
Interest in digital approaches to clinical protocols has grown steadily as sponsors, solution providers, sites, and regulators explore ways to make study planning and execution more efficient. Read the full article featuring Rob DiCicco from Clinical Leader here.
Scrip Asks… What Does 2026 Hold For Biopharma? Part 2: Competitive Dynamics – A Landscape Reshaped
Regulatory divergence across major markets is creating strategic complexity that compounds geographic competitive pressures. Read the full article featuring Allison Cuff Shimooka from Citeline here.
TransCelerate CEO Janice Chang wants trials to become part of routine care
Clinical trials are drowning in data. In a TransCelerate/Tufts analysis published in late 2025, phase 3 protocols averaged more than 5.9 million data points, up 67% since 2020. Read the full article featuring Janice Change from Drug Discovery Trends here.
